Literature DB >> 31500928

MiR-1307 influences the chemotherapeutic sensitivity in ovarian cancer cells through the regulation of the CIC transcriptional repressor.

Yingying Zhou1, Min Wang2, Ting Shuang3, Yisi Liu4, Yongqi Zhang5, Cong Shi6.   

Abstract

BACKGROUND: Extended from our previously observation that expression of miR-1307 in chemoresistant primary ovarian cancer tissues is elevated, here we are aiming to dissect the function of miR-1307 and its predicted target gene, CIC (capicua transcriptional repressor), in ovarian cancer chemotherapy.
METHODS: We evaluated the expression of miR-1307 and CIC in chemoresistant and chemosensitive ovarian cancer tissues and cells by real time-PCR and western blot. We used chemoresistant/chemosensitive cells with miR-1307 suppression/overexpression to study the biological effects of miR-1307 by MTT and flow cytometer. Dual luciferase reporter gene assay was used to validate direct binding between miR-1307 and the 3'-UTR of CIC. Real-time PCR and western blot analyses, MTT and flow cytometry were used to reveal the biological effects of miR-1307 and CIC, as well as their regulation.
RESULTS: We found that miR-1307 affects cell cycle dynamics, cell viability in ovarian cancer cells. In addition, its expression level can influence chemosensitivity to paclitaxel in ovarian cancer cells. We also validate that CIC is a downstream target of miR-1307 via its regulation on 3'-UTR of CIC gene and ETV4 and ETV5 are also regulated by miR-1307/CIC axis.
CONCLUSIONS: Our data suggested that miR-1307 may be involved in the resistance of ovarian cancer to chemotherapy drugs via regulation of CIC, and should be further explored as a potential therapeutic target.
Copyright © 2019 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  CIC; Chemoresistant; Chemosensitive; Ovarian cancer; RTK signaling; miR-1307

Mesh:

Substances:

Year:  2019        PMID: 31500928     DOI: 10.1016/j.prp.2019.152606

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  5 in total

Review 1.  A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.

Authors:  Ahmad Saburi; Mohammad Saeed Kahrizi; Navid Naghsh; Hasti Etemadi; Ahmet İlhan; Ali Adili; Shadi Ghoreishizadeh; Rozita Tamjidifar; Morteza Akbari; Gülinnaz Ercan
Journal:  J Ovarian Res       Date:  2022-07-07       Impact factor: 5.506

2.  Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage.

Authors:  Pietro Carotenuto; Francesco Amato; Andrea Lampis; Colin Rae; Somaieh Hedayat; Maria C Previdi; Domenico Zito; Maya Raj; Vincenza Guzzardo; Francesco Sclafani; Andrea Lanese; Claudia Parisi; Caterina Vicentini; Ian Said-Huntingford; Jens C Hahne; Albert Hallsworth; Vladimir Kirkin; Kate Young; Ruwaida Begum; Andrew Wotherspoon; Kyriakos Kouvelakis; Sergio Xavier Azevedo; Vasiliki Michalarea; Rosie Upstill-Goddard; Sheela Rao; David Watkins; Naureen Starling; Anguraj Sadanandam; David K Chang; Andrew V Biankin; Nigel B Jamieson; Aldo Scarpa; David Cunningham; Ian Chau; Paul Workman; Matteo Fassan; Nicola Valeri; Chiara Braconi
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

3.  Long non-coding RNA OIP5-AS1 suppresses microRNA-92a to augment proliferation and metastasis of ovarian cancer cells through upregulating ITGA6.

Authors:  Yujue Wang; Lingling Li; Xun Zhang; Xiaolan Zhao
Journal:  J Ovarian Res       Date:  2022-02-16       Impact factor: 4.234

4.  Identification of epigenetic dysregulation gene markers and immune landscape in kidney renal clear cell carcinoma by comprehensive genomic analysis.

Authors:  Linli Xie; Shuang Wu; Rong He; Sisi Li; Xiaodan Lai; Zhe Wang
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

Review 5.  Capicua in Human Cancer.

Authors:  Ji Won Kim; Rovingaile Kriska Ponce; Ross A Okimoto
Journal:  Trends Cancer       Date:  2020-09-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.